The introduction of inhibitors of the cyclic GMP phosphodiesterase (PDE) 5 into clinical urology is mainly the result of the characterization of the physiology of nonvascular and vascular penile ...

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...

Learn how common medications like nitroglycerin, antidepressants, and hormone therapies can trigger migraine attacks. Discover ways to manage and discuss options with healthcare providers.

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.

The dose of phosphodiesterase type-5 inhibitors varies depending upon what is being treated. The 2022 US study included men and women with pulmonary hypertension only. The UK study only had men ...

Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific ...

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without ...

A new study reports that mirodenafil, a newly developed oral phosphodiesterase type 5 (PDE5) inhibitor, is an efficacious and safe treatment for erectile dysfunction (ED). Many men with ED ...

Phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil) enhance nitric oxide production and can cause potentially fatal hypotension when used in combination with nitrates. Nitrates ...

Objective: Given the therapeutic and non-therapeutic use of the tadalafil, (phosphodiesterase-5 inhibitor, PDE-5i), we examined its effects on anaerobic performance indices. Methods: In total, 12 well ...